Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...
Arcturus: Downgrading As mRNA Promise Meets Market Reality
Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...
SEC Oil Fraud Case Gets Nod for Over $10 Million in Remedies
Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 ...
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research
BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...
BTIG sets $41 target for Arcturus stock, cites strong prospects
BTIG analysts began covering Arcturus Therapeutics (NASDAQ:ARCT) with a positive outlook, assigning a Buy rating and establishing a price target of $41.00. Currently trading at $16.49 with a market ...
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews
In the assessment of 12-month price targets, analysts unveil insights for Arcturus Therapeutics, presenting an average target ...
Leerink Partnrs Has Bullish Outlook for ARCT FY2024 Earnings
Equities research analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arcturus Therapeutics in a note ...
Arcturus Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of Arcturus Therapeutics (ARCT) with a Buy rating and $41 price target Arcturus is a commercial-stage biotechnology ...
Arcturus Therapeutics: Anticipated Growth through Innovative Therapies and Strategic Trials
Wells Fargo analyst Yanan Zhu has maintained their bullish stance on ARCT stock, giving a Buy rating on January 15.Stay Ahead of the ...